194 results on '"Golding, Basil"'
Search Results
2. A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection
3. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation
4. Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern
5. Considerations on activity assay discrepancies in factor VIII and factor IX products
6. Dosing Considerations for Antibodies Against COVID-19
7. Considerations for pharmacokinetic assessment of immunoglobulins: Gammagard in very low birth weight neonates with and without baseline-correction
8. Dosing Strategy of Immunoglobulin (IgG) Replacement Therapies in Obese and Overweight Patients with Primary Immunodeficiency Diseases (PIDDs): A Meta‐Analysis of Clinical Trials
9. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16+ NK cell activation.
10. Ablation as First-Line Treatment for Asymptomatic Atrial Fibrillation in the Context of Conduction Disturbances: Case Report
11. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins
12. Fusion partners matter: Factor VIII light chain binding enables CD16-mediated recombinant Factor VIII-Fc fusion protein natural killer cell activation.
13. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity
14. Regulatory Framework for Hemoglobin-Based Oxygen Carrier Trials
15. A Single Treatment with Adjuvant Stimulates Th1-Like Cytokines and Downregulates Th2-Mediated Primary and Secondary Allergic Responses
16. 1918 pandemic influenza virus and Streptococcus pneumoniae co-infection results in activation of coagulation and widespread pulmonary thrombosis in mice and humans
17. Ablation as first-line treatment for asymptomatic atrial fibrillation in the context of conduction disturbances: Case report
18. Common Sequence in HIV-1 GP41 and HLA Class II Beta Chains can Generate Crossreactive Autoantibodies with Immunosuppressive Potential Early in the Course of HIV-1 Infection
19. Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters
20. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report
21. Factor VIII-Fc Activates Natural Killer Cells via Fc-Mediated Interactions With CD16
22. Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters.
23. Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
24. Hyperimmune globulins and same-day thrombotic adverse events as recorded in a large healthcare database during 2008–2011
25. Epitope Diversity and SARS-CoV-2 Variants Neutralizing Capacity of SARS-CoV-2 Hyperimmune Intravenous Immunoglobulins for Treatment of COVID-19
26. Dosing Considerations for Antibodies Against COVID-19
27. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization
28. Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010
29. Production of human α1 proteinase inhibitor from Aspergillus niger
30. Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence
31. Programming of CTL with heat-killed Brucella abortus and antigen allows soluble antigen alone to generate effective secondary CTL
32. Identification of a novel immunodominant cytotoxic T lymphocyte epitope derived from human factor VIII in a murine model of hemophilia A
33. Systemic and mucosal immunity in rhesus macaques immunized with HIV-1 peptide and gp120 conjugated to Brucella abortus
34. Mucosal immunity in mice immunized with HIV-1 peptide conjugated to Brucella abortus
35. Expression of human α1-proteinase inhibitor in Aspergillus niger
36. Fusion of Fc domain to Factor IX (FIX) modulates the Th2 biased response to FIX and triggers Th1 immunity in hemophilia B treated mice.
37. Fc-fusion drugs have C1q/FcγR binding and signaling properties that can affect their immunogenicity.
38. Association of immune globulin intravenous and thromboembolic adverse events
39. 1918 pandemic influenza virus and Streptococcus pneumoniae coinfection results in activation of coagulation and widespread pulmonary thrombosis in mice and humans
40. Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5
41. 1918 pandemic influenza virus andStreptococcus pneumoniaeco-infection results in activation of coagulation and widespread pulmonary thrombosis in mice and humans
42. Immune responses to chimeric human-FIX-mouse-Fc fusion protein in a hemophilia B mouse model (THER2P.963)
43. Fc fusion as a platform technology: potential for modulating immunogenicity
44. Critical Role of the Liver in Coagulation
45. Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012
46. Poly (I:C) induces human endothelial barrier dysfunction by disrupting tight junction expression of claudin-5 (P4197)
47. Plasma derivatives: New products and new approaches
48. Aptamers as a Sensitive Tool to Detect Subtle Modifications in Therapeutic Proteins
49. Use of Toll-Like Receptor Assays To Detect and Identify Microbial Contaminants in Biological Products
50. Production, purification, and characterization of human α1 proteinase inhibitor fromAspergillus niger
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.